The funny and sad thing about that article is that there is no mention all trials for it have been stopped and that company is letting collect dust as I write and has been for a few months now with no real guidance when and if the trial will ever start again. The article also omits the fact that Amarantus is struggling to stay alive. Must have been a paid piece because if it wasn't the person writing it is one horrible journalist.
(3)
(2)
Amarantus Bioscience Holdings (AMBS) Stock Research Links